{"id":"ak117","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AK117 works by binding to CD47 and blocking its interaction with SIRPα on the surface of myeloid cells, thereby preventing immune suppression and enhancing anti-tumor immune responses.","oneSentence":"AK117 is a small molecule targeting the CD47/SIRPα axis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:20:32.990Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory multiple myeloma"}]},"trialDetails":[{"nctId":"NCT05227664","phase":"PHASE2","title":"A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2022-03-23","conditions":"Metastatic Triple-negative Breast Cancer, Locally Advanced Triple-negative Breast Cancer","enrollment":120},{"nctId":"NCT05229497","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2022-05-04","conditions":"Advanced Malignant Tumors","enrollment":154},{"nctId":"NCT06953999","phase":"PHASE3","title":"A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Akeso","startDate":"2025-06-11","conditions":"Pancreatic Cancer","enrollment":999},{"nctId":"NCT05214482","phase":"PHASE1, PHASE2","title":"A Study of AK112 in Advanced Malignant Tumors","status":"COMPLETED","sponsor":"Akeso","startDate":"2022-01-22","conditions":"Advanced Malignant Tumors","enrollment":154},{"nctId":"NCT06789848","phase":"PHASE2","title":"Ligufalimab and Cadonilimab in Advanced Liver Cancers","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2025-02-18","conditions":"Advanced Hepatocellular Carcinoma, Refractory Hepatocellular Carcinoma, Biliary Tract Cancer","enrollment":64},{"nctId":"NCT07264075","phase":"PHASE3","title":"Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN","status":"NOT_YET_RECRUITING","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2026-01","conditions":"Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)","enrollment":780},{"nctId":"NCT07245446","phase":"PHASE2","title":"A Study of Ivonescimab in First-Line ES-SCLC","status":"RECRUITING","sponsor":"Akeso","startDate":"2025-10-29","conditions":"Extensive-stage Small Cell Lung Cancer (ES-SCLC)","enrollment":180},{"nctId":"NCT05382442","phase":"PHASE2","title":"A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2022-06-27","conditions":"Metastatic Colorectal Cancer","enrollment":254},{"nctId":"NCT04728334","phase":"PHASE1","title":"A Phase 1 Dose Escalation and Expansion Study of AK117","status":"COMPLETED","sponsor":"Akeso","startDate":"2021-03-23","conditions":"Neoplasms Malignant","enrollment":49},{"nctId":"NCT04980885","phase":"PHASE1, PHASE2","title":"A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2021-08-13","conditions":"Acute Myeloid Leukemia","enrollment":68},{"nctId":"NCT04900350","phase":"PHASE1, PHASE2","title":"A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2021-06-18","conditions":"Myelodysplastic Syndrome","enrollment":136},{"nctId":"NCT06642792","phase":"PHASE1, PHASE2","title":"A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Akeso","startDate":"2025-01-17","conditions":"Classic Hodgkin Lymphoma","enrollment":280},{"nctId":"NCT06196203","phase":"PHASE2","title":"A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes","status":"RECRUITING","sponsor":"Akeso","startDate":"2024-02-07","conditions":"Higher-risk Myelodysplastic Syndromes","enrollment":90},{"nctId":"NCT06601335","phase":"PHASE3","title":"A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)","status":"RECRUITING","sponsor":"Akeso","startDate":"2024-10-30","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":510},{"nctId":"NCT04349969","phase":"PHASE1","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination With AK104","status":"COMPLETED","sponsor":"Akesobio Australia Pty Ltd","startDate":"2020-04-23","conditions":"Neoplasms Malignant","enrollment":38},{"nctId":"NCT06508606","phase":"PHASE2","title":"AK117 (Anti-CD47) + Anti-EGFR for R/M HNSCC","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2024-08-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":10},{"nctId":"NCT06387420","phase":"PHASE1, PHASE2","title":"A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Akeso","startDate":"2024-04-29","conditions":"ACUTE MYELOID LEUKEMIA; AML","enrollment":180},{"nctId":"NCT05960955","phase":"PHASE2","title":"Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Akeso","startDate":"2023-11-13","conditions":"Resectable Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":90},{"nctId":"NCT05235542","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors","status":"UNKNOWN","sponsor":"Akeso","startDate":"2022-07-12","conditions":"Advanced Malignant Tumors","enrollment":130}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AK117","genericName":"AK117","companyName":"Akeso","companyId":"akeso","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AK117 is a small molecule targeting the CD47/SIRPα axis. Used for Relapsed or refractory multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}